Загрузка...
Nucleolin and ErbB2 inhibition reduces tumorigenicity of ErbB2-positive breast cancer
ErbB2, a member of the ErbB family of receptor tyrosine kinases, is an essential player in the cell’s growth and proliferation signaling pathways. Amplification or overexpression of ErbB2 is observed in ∼30% of breast cancer patients, and often drives cellular transformation and cancer development....
Сохранить в:
| Опубликовано в: : | Cell Death Dis |
|---|---|
| Главные авторы: | , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Nature Publishing Group UK
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5833446/ https://ncbi.nlm.nih.gov/pubmed/29352243 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-017-0067-7 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|